133 related articles for article (PubMed ID: 15246912)
1. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure.
Dickstein K; De Voogd HJ; Miric MP; Willenbrock R; Mitrovic V; Pacher R; Koopman PA
Am J Cardiol; 2004 Jul; 94(2):237-9. PubMed ID: 15246912
[TBL] [Abstract][Full Text] [Related]
2. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans.
Seed A; Kuc RE; Maguire JJ; Hillier C; Johnston F; Essers H; de Voogd HJ; McMurray J; Davenport AP
Life Sci; 2012 Oct; 91(13-14):743-8. PubMed ID: 22480515
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
Tikkanen I; Tikkanen T; Cao Z; Allen TJ; Davis BJ; Lassila M; Casley D; Johnston CI; Burrell LM; Cooper ME
J Hypertens; 2002 Apr; 20(4):707-14. PubMed ID: 11910307
[TBL] [Abstract][Full Text] [Related]
4. Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure.
Mulder P; Barbier S; Monteil C; Jeng AY; Henry JP; Renet S; Thuillez C
J Cardiovasc Pharmacol; 2004 Apr; 43(4):489-94. PubMed ID: 15085059
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats.
Thöne-Reinke C; Simon K; Richter CM; Godes M; Neumayer HH; Thormählen D; Hocher B
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S76-9. PubMed ID: 15838365
[TBL] [Abstract][Full Text] [Related]
6. Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner.
Kalk P; Sharkovska Y; Kashina E; von Websky K; Relle K; Pfab T; Alter M; Guillaume P; Provost D; Hoffmann K; Fischer Y; Hocher B
Hypertension; 2011 Apr; 57(4):755-63. PubMed ID: 21339476
[TBL] [Abstract][Full Text] [Related]
7. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
Daull P; Benrezzak O; Arsenault D; Pheng LH; Blouin A; Cayer J; Beaudoin M; Belleville K; Sirois P; Nantel F; Jeng AY; Battistini B
Am J Hypertens; 2005 Dec; 18(12 Pt 1):1606-13. PubMed ID: 16364833
[TBL] [Abstract][Full Text] [Related]
8. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats.
Emoto N; Raharjo SB; Isaka D; Masuda S; Adiarto S; Jeng AY; Yokoyama M
Hypertension; 2005 Jun; 45(6):1145-52. PubMed ID: 15897363
[TBL] [Abstract][Full Text] [Related]
9. Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats.
Trapani AJ; Beil ME; Bruseo CW; Fink CA; Hoyer D; Savage P; Jeng AY
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():102S-106S. PubMed ID: 12193065
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic properties of SOL1: a novel dual inhibitor of neutral endopeptidase and endothelin converting enzyme.
Nelissen J; Lemkens P; Sann H; Bindl M; Bassissi F; Jasserand D; De Mey JG; Janssen BJ
Life Sci; 2012 Oct; 91(13-14):587-92. PubMed ID: 22365954
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of neointima formation in an organ culture of human saphenous vein: a comparison of dual endothelin-converting enzyme/neutral endopeptidase and selective neutral endopeptidase inhibition.
Porter KE; Dickinson T; London NJ
J Vasc Surg; 2001 Sep; 34(3):548-54. PubMed ID: 11533610
[TBL] [Abstract][Full Text] [Related]
12. Chronic effects of an endothelin-converting enzyme inhibitor on cardiorenal and hormonal function in heart failure.
Wada A; Ohnishi M; Tsutamoto T; Fujii M; Matsumoto T; Yamamoto T; Wang X; Kinoshita M
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():254S-257S. PubMed ID: 12193098
[TBL] [Abstract][Full Text] [Related]
13. CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
Trapani AJ; De Lombaert S; Beil ME; Bruseo CW; Savage P; Chou M; Jeng AY
Life Sci; 2000; 67(9):1025-33. PubMed ID: 10954036
[TBL] [Abstract][Full Text] [Related]
14. Triple vasopeptidase inhibition of angiotensin-converting enzyme/neutral endopeptidase/endothelin-converting enzyme activities on the hemodynamic profile of chronically instrumented unrestrained conscious spontaneously hypertensive rats.
Daull P; Blouin A; Sirois P; Nantel F; Jeng AY; Battistini B
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S398-401. PubMed ID: 15838331
[TBL] [Abstract][Full Text] [Related]
15. CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
Jeng AY; Savage P; Beil ME; Bruseo CW; Hoyer D; Fink CA; Trapani AJ
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():98S-101S. PubMed ID: 12193064
[TBL] [Abstract][Full Text] [Related]
16. Triple ACE-ECE-NEP inhibition in heart failure: a comparison with ACE and dual ECE-NEP inhibition.
Mellin V; Jeng AY; Monteil C; Renet S; Henry JP; Thuillez C; Mulder P
J Cardiovasc Pharmacol; 2005 Sep; 46(3):390-7. PubMed ID: 16116347
[TBL] [Abstract][Full Text] [Related]
17. Emerging concepts of neurohumoral modulation in the treatment of congestive heart failure.
Mulder P; Thuillez Ch
Arch Mal Coeur Vaiss; 2002 Sep; 95(9):821-6. PubMed ID: 12407798
[TBL] [Abstract][Full Text] [Related]
18. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme.
Battistini B; Daull P; Jeng AY
Cardiovasc Drug Rev; 2005; 23(4):317-30. PubMed ID: 16614731
[TBL] [Abstract][Full Text] [Related]
19. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.
Kukkola PJ; Savage P; Sakane Y; Berry JC; Bilci NA; Ghai RD; Jeng AY
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S65-8. PubMed ID: 8587470
[TBL] [Abstract][Full Text] [Related]
20. Protective effects of a dual endothelin converting enzyme/neutral endopeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat.
Dai ZK; Hsieh CC; Chai CY; Wu JR; Jeng AY; Chou SH; Wu BN; Yeh JL; Chen IJ; Tan MS
Pediatr Pulmonol; 2010 Nov; 45(11):1076-85. PubMed ID: 20658482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
